Mbx Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
MBX Biosciences reports a widening net loss in Q2 2026 driven by increased research and development expenses, though the company maintains a substantial cash reserve and advances its pipeline.
NASDAQ
MBX Biosciences reports a net loss of $23.5 million for Q1 2026, with decreased R&D expenses but higher G&A costs, while maintaining a substantial cash reserve of $440 million.
NASDAQ
MBX Biosciences reported increased net losses for Q3 2025 but maintains strong liquidity to fund operations into 2029, driven by a recent $187.4 million public offering and positive clinical trial progress.
NASDAQ
MBX Biosciences reports increased R&D spend and net losses in Q2 2025, while advancing its lead drug candidates and extending its cash runway into mid-2027.
NASDAQ
MBX Biosciences reports increased R&D spending and a net loss for Q1 2025, while advancing its clinical programs for endocrine and metabolic disorders.
NASDAQ
MBX Biosciences reports a net loss of $18.1 million for the third quarter of 2024, alongside a significant increase in cash and marketable securities following its IPO.